Background: Tumor mutation burden (TMB), DNA mismatch repair deficiency (dMMR), microsatellite instability (MSI), and PD-L1 amplification (PD-L1 AMP) may predict the efficacy of PD-1/PD-L1 blockade. In this study, we aimed to characterize the distributions of these biomarkers in over 1,000 Chinese patients with cancer.
Introduction
The PD-1/PD-L1 blockade has become a powerful approach for treating multiple types of cancer. Many patients benefit from such treatments, exhibiting not only a higher objective response rate but also durable remission for many years. [1] [2] [3] [4] [5] [6] [7] While treatment with PD-1/PD-L1 blockade can be highly effective, not every patient or cancer type responds to these inhibitors 8 , and some patients experience hyper progression after immunotherapy. 9 Identifying which patients may benefit from these inhibitors is one of the most significant current challenges. Therefore, the identification of precise biomarkers to predict the efficacy of PD-1/PD-L1 blockade is critical.
Recently, five clinical trials across 15 cancer types involving 149 patients with high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR) reported complete or partial response to pembrolizumab in 39.6% of patients. Moreover, among 78% of the responding patients, the response lasted for 6 months or longer. 10, 11 These results accelerated the FDA approval of this treatment for unresectable or metastatic solid tumors in patients with MSI-H or dMMR. 12 Another emerging biomarker is high tumor mutation burden (TMB-H), which is closely related to the PD-1/PD-L1 blockade response. Melanomas have the highest mutational loads among human tumors and also exhibit an unusually high response rate of 30-40% to the PD-1/PD-L1 blockade. Urothelial carcinoma, NSCLC, and head and neck squamous cell carcinoma have the next highest median mutational loads and respond 5 to the PD-1/PD-L1 blockade at rates above 15%. In contrast, glioblastoma and pancreatic, ovarian, and prostate cancer, which have relatively low median mutational loads, show little response to PD-1 blockade treatment. 13 Finally, research has identified PD-L1 (CD274) amplification (PD-L1 AMP) as a predictor of response to PD-1/PD-L1 blockade therapy. In classical Hodgkin lymphoma, 97% of patients exhibit PD-L1 AMP. 14 
Compared with other cancers, patients with
Hodgkin lymphoma exhibit a higher overall response rate, reaching 69%. 15, 16 In rare metastatic basal cell carcinoma, PD-L1 AMP is also related to response to nivolumab. 17 Thus, there is a strong correlation between PD-L1 AMP and response to the PD-1/PD-L1 blockade.
Given that the above markers are potential biomarkers of PD-1/PD-L1 blockade efficacy, we aimed to characterize the distributions of these biomarkers in over 1,000
Chinese patients with cancer using exome profiling data. We also explored the relationships among TMB, MSI-H, dMMR, and PD-L1 AMP.
Methods

Patient characteristics
We collected over 1,000 Chinese cancer specimens from more than 70 hospitals in 20
Chinese provinces from October 2015 to March 2016. In total, there were 1,179 samples, including 524 biopsy samples and 655 formalin-fixed, paraffin-embedded 6 (FFPE) samples. Blood samples were also collected as controls. All procedures followed the Molecular Pathology Clinical Practice Guidelines and Reports 18 and were performed in accordance with the 1964 Declaration of Helsinki. Informed consent was obtained from each of the participants.
Whole-exome sequencing (WES) analysis
The complete exomes of tumor samples and matched blood samples were sequenced in each patient. DNA was fragmented and hybridized to the SureSelect Human All Exome Kit V5 (Agilent Technologies, Santa Clara, CA, USA), containing exon sequences from 27,000 genes. Exome shotgun libraries were sequenced on the Illumina Xten platform, generating paired-end reads of 150 bp at each end. Image analysis and base calling were performed with CAVSAVR (Illumina, San Diego, CA, USA) using default parameters.
Sequencing adaptors and low-quality reads were removed to obtain high-quality reads.
These were aligned to the NCBI human reference genome hg19 using the Burrows-Wheeler Aligner alignment algorithm. 19 We used the Genome Analysis Toolkit (GATK, version 3.5) to process reads. Localized insertion-deletion (indel) realignments were performed by GATK. GATK Realigner Target Creator was used to identify regions for realignment. For single-nucleotide variant (SNV) calling, the MuTect algorithm was applied to identify candidate somatic SNVs in tumors by comparison with the matched control blood sample from each patient. SNV annotation was performed by ANNOVAR. We used dbNSFP31 to predict 7 nonsynonymous mutations in the encoded proteins. For dMMR, we identified SNVs in MLH1, MSH2, MSH6, and PMS2.
For indel detection, tumor and blood samples were analyzed with VarscanIndel.
Candidate somatic indels were identified based on the following criteria: (1) supported by at least five reads and (2) the number of supporting reads divided by the maximum read depth at the left, and right breakpoint positions were > 0.05. All somatic indel calls were manually checked with the Integrative Genomics Viewer.
The CNVnator software tool was used to detect somatic copy number variations (CNVs). 20 All parameters were set to their defaults for filtering samples, and the bin size was set to 50-60 according to the average coverage depth. A PD-L1 copy number ≥ 3 was defined as PD-L1 AMP.
TMB evaluation
TMB was defined by the total number of nonsynonymous somatic mutations (NSM), which was determined by comparing sequence data between tumor tissues and matched blood samples using a previously described method. 21 We defined the higher tertile of the TMB of each cancer type as the threshold for TMB-H according to the method of a prior study. 22 8 All autosomal microsatellite tracts containing five or more repeating subunits 1-5 bp in length in GRCh37/hg19 were identified using MISA (http://pgrc.ipkgatersleben.de/misa/misa.html). Detailed calculations were performed as described previously. 23 Patients were classified into the microsatellite stable (MSS), low MSI (MSI-L), and high MSI (MSI-H) groups with 0-1%, 1-3.5%, and ≥3.5% unstable microsatellite sites, respectively, according to a previous method. 24
MSI evaluation
Results
Cohort description
We collected 1,197 tumor samples from Chinese patients. Due to unqualified samples and sequencing failures, 953 samples were successfully sequenced by WES. These tumors encompassed four principal tumor types, including CRC and lung, breast, and gastric cancer, accounting for up to 78% of the tumors. There were also more than eight other types of tumor ( Figure 1 ). Based on the cancer distribution in China, 25 we collected more lung adenocarcinoma (LUAD) cases (n = 172) than lung squamous cell carcinoma (LUSC) cases (n = 42) and other subtypes (n = 37). Among breast cancer cases, the number of patients with HER2 + (n = 34), HER2 -(n = 49), and HER2 status unknown (n = 68) cancer were similar.
TMB profiling
We analyzed the TMB of the 953 Chinese patients with cancer. The median TMB of each cancer type ranged from 36 to 273 NSM, with an overall median of 95 NSM, 9 and 54 patients exhibited NSM values > 1000. The two cancer types with the highest TMB were lung cancer and CRC, with median TMB of 176 and 108 NSM, respectively. Hepatocellular carcinoma, renal cell carcinoma, and glioma also had high TMB values, while the lowest TMB was observed among gastrointestinal stromal tumors. We also found that different tumor subtypes exhibited different TMB, especially in lung cancer: LUSC cases had median TMB values more than three times higher than those in LUAD cases (273 vs. 74 NSM, respectively) ( Figure 2A ).
Although PD-1/PD-L1 blockade has been approved in NSCLC, some clinical trials have reported that NSCLC patients with EGFR mutations do not benefit from this therapy and that it may even lead to a more rapid disease progression. 2, 10, 26 Therefore, we compared the median TMB of LUAD patients with mutant (n = 77) and wild-type (n = 99) EGFR genes. Patients with EGFR mutations had significantly lower median TMB compared with those with wild-type EGFR (74 vs. 113 NSM, respectively; P = 0.0039) ( Figure 2B ).
MSI and dMMR distributions
We investigated the MSI and dMMR distributions in Chinese patients with cancer.
Tumors were classified into three groups based on the proportion of unstable microsatellites, consistent with previous reports 24 : MSS, below 0-1% (n = 597); MSI-L, 1-3.5% (n = 12); and MSI-H, ≥3.5% (n = 28). The frequency of tumors classified as MSI-H was 14% for CRC and 4% for gastric cancer, while lung and breast cancer exhibited MSI-H frequencies below 3% ( Figure 3A ). Gastrointestinal stromal tumors exhibited a high frequency of dMMR, while those of hepatocellular carcinoma, sarcoma of soft tissue, and renal cell carcinoma were among the lowest. The dMMR frequency of lung carcinoma (other types) was nearly double those in LUAD and LUSC. HER2breast carcinoma exhibited a higher dMMR frequency than HER2 + / HER2 unknown breast carcinoma ( Figure 3B ).
PD-L1 AMP distribution
We analyzed the distribution of PD-L1 AMP among Chinese patients with cancer. We observed that PD-L1 AMP occurred most frequently in LUSC (14.3%), and HER2 + breast cancer (8.8%), and breast cancer with unknown HER2 status (5.8%). In contrast, LUAD and CRC had lower rates of PD-L1 AMP at 1.75% and 1.59%, respectively ( Figure 4 ). Thus, LUAD and LUSC exhibit large differences in levels of PD-L1 AMP.
Relationships among biomarkers
In addition to exploring the distributions of the four biomarkers in Chinese patients with a wide variety of tumor types, we also analyzed the correlations among these biomarkers. As shown in Figure 5A , the four biomarkers overlap with each other.
Among 337 Chinese patients with cancer showing TMB-H, 11.28% are also positive for dMMR, 7.4% for MSI-H, and 2.7% for PD-L1 AMP. In addition, 9 cases in the TMB-H cohort also exhibited MSI-H and dMMR simultaneously, while one patient was positive for all four biomarkers. Up to 76.26% of TMB-H tumors did not coincide with any of the other biomarkers ( Figure 5B ). In conclusion, TMB-H is a relatively independent biomarker with a small overlap with other biomarkers.
We also calculated the TMB values of patients with amplified and normal PD-L1. The median values of TMB in the two groups were 94 and 95 NSM, respectively, reflecting no significant difference between the two groups ( Figure 5C ). Moreover, 34.6% of PD-L1 AMP patients were classified as TMB-H. These results suggest that the correlation between TMB-H and PD-L1 AMP is small. Thus, it is necessary to simultaneously detect both in order to identify more suitable cancer patients for immune therapy.
Furthermore, we investigated the correlations between MSI-H and the other three biomarkers. MSI arises from mutations or epigenetic alterations in the MMR proteins (MLH1, MSH2, MSH3, MSH6, PMS1, or PMS2). 27, 28 As anticipated, we found a correlation between MSI-H and dMMR: 32.14% of Chinese patients with cancer showing MSI-H exhibited dMMR, and those cancer patients were also TMB-H ( Figure   6A ). Thus, while MSI-H and dMMR were correlated, the association was not particularly strong, suggesting that MSI-H may also be caused by additional factors.
MSI-H tumors exhibit high levels of neoantigen, causing strong local and systemic immune responses. 29 Therefore, it is necessary to investigate the relationship between MSI and TMB. The median TMB values of the MSI-H, MSI-L, and MSS groups were 1945, 408, and 90 NSM per tumor, respectively, reflecting significant differences among groups ( Figure 6B ). About 89% of Chinese patients with cancer exhibiting MSI-H status were classified in the TMB-H group.
We also found a remarkable correlation between dMMR and TMB-H in CRC A comparison of the TMB values of dMMR patients (n = 15) and MMR-proficient patients (n = 237) showed that increased TMB was significantly associated with dMMR (P < 0.0001). dMMR tumors on average had 15-fold more NSM (1567 vs. 106 NSM) than MMR-proficient patients ( Figure 6C ).
In each of the MSI-H and dMMR groups, there were only two cases with PD-L1 AMP, representing rates of 7% and 4%, respectively. PD-L1 AMP cases also exhibited low frequencies of dMMR and MSI-H (<10% each), which is consistent with a previous report showing that among 365 solid tumors only the 10.9% of MSI-H cases exhibited PD-L1 AMP. 30
Discussion
To our knowledge, this is the first study characterizing TMB, MSI, dMMR, and PD-L1 AMP in Chinese patients with more than 18 tumor types, as determined by WES. The incidence rates in TMB-H, MSI-H, dMMR, and PD-L1 AMP were 35%, 4%, 0.53% and 0.04% respectively.
Chinese patients with cancer exhibited a characteristic pattern of TMB. The two cancer 13 types with the highest TMB were lung cancer and CRC, similar to the results of prior studies. 31, 32 In contrast, hepatocellular carcinoma, breast cancer, and esophageal cancer cases exhibited TMB values 1-3 times higher than those in The Cancer Genome Atlas (TCGA) cohort. 33 The CHECKMATE-040 and APHINITY trials showed that adjuvant treatment with nivolumab and pertuzumab effectively improved the overall response rate of hepatocellular carcinoma previously treated with sorafenib and the invasive disease-free survival of HER2 + breast cancer. 34, 35 This indicates that more Chinese hepatocellular carcinoma, breast cancer, and esophageal cancer patients could benefit from the PD-1/PD-L1 blockade and that TMB can be used as a potential immunotherapeutic biomarker.
We collected more LUAD patients than LUSC patients, and we found that the TMB values of two types differed among Chinese patients. In contrast, the prevalence of TMB-H among LUAD patients is similar to that among LUSC patients in TCGA. 33 Moreover, in clinical trials, the treatment of both advanced squamous and nonsquamous NSCLC with nivolumab resulted in similar improvements over treatment with docetaxel, with overall survival rates of 42% and 51% and response rates of 20% and 19%, respectively. 2, 36 Similarly, in a trial with nivolumab as the first-line treatment for advanced NSCLC, squamous and non-squamous groups had similar median progression-free and overall survival. 37 Based on our findings, however, Chinese patients with LUSC may demonstrate the higher potential for clinical benefits of the PD-1/PD-L1 blockade. In addition, we found that patients with EGFR mutations had 14 significantly lower median TMB compared with those with wild-type EGFR, consistent with another study in which the TMB value of EGFR-mutant non-squamous NSCLC was half that of wild-type. 38 This result may help to explain why in EGFR-mutant advanced NSCLC, immune checkpoint blockade does not improve overall survival over that achieved with docetaxel alone.
Several studies have analyzed the correlation between TMB and the efficacy of immunotherapy in detail, and all have shown high concordance between TMB and treatment efficacy. 13, 39, 40 A study containing 151 cancer patients further confirmed a linear relationship between TMB and the clinical outcome of immunotherapy. 39 Moreover, the cut-off value of TMB to predict treatment response has been determined in several studies. Another study involving melanoma and NSCLC clinical data found the cut-off to be 192 NSM, with a 74% sensitivity and 59.3% specificity. 31 In this study, more than 20% of patients with LUSC, other subtypes of lung carcinoma, hepatocellular carcinoma, glioma, esophageal carcinoma, and CRC had NSM counts above 192, indicating that TMB-H may be a good indicator for the use of PD-1/PD-L1 blockade. However, the optimal TMB cut-offs require further exploration in clinical trials with Chinese patients with cancer in order to guide the use of immunotherapy.
In the current study, the frequency of tumors classified as MSI-H was 14% for CRC, while lung and breast cancer exhibited MSI-H frequencies below 3%. By contrast, a comprehensive review of studies that investigated MSI before 2014 showed that CRC 15 exhibited MSI-H frequencies >10%, while that of lung cancer was <2%. 41 Although the distributions of MSI-H in Chinese patients with cancer observed in this study were consistent with those in cancer patients in other countries, the frequency of MSI-H in gastric cancer is very low (4%), and the rates of MSI-H in cancer patients from other countries were 18-22%. 41, 42 This suggests that MSI-H may not be useful in screening gastric patients before PD-1/PD-L1blocker and that other biomarkers or a combination of MSI-H with other biomarkers should be investigated further.
Compared with TMB and MSI, research involving the frequency of PD-L1 AMP in many cancer types is lacking. In this study, we fully surveyed PD-L1 AMP in Chinese patients with cancer. We found relatively high rates in LUSC (14.3%), HER2 + breast cancer (8.8%), and breast cancer with unknown HER2 status (5.8%), and low rates in LUAD (1.75%) and CRC (1.59%). In other studies, rates of PD-L1 AMP of 29% in triple-negative breast cancer, 5% in glioblastoma, and 3% in CRC have been observed. 43, 44 A study of more than 100,000 patients with many cancer types also surveyed the PD-L1 AMP distribution. 45 In this study, sarcomatoid kidney carcinoma and nasopharyngeal cancer exhibited rates of PD-L1 AMP over 5%, while LUAD, CRC, and breast cancer exhibited rates of 0.6%, 0.2%, and 2%, respectively. Thus, rates of PD-L1 AMP among Chinese patients with LUAD, breast cancer, and CRC were similar to those observed in other studies.
While TMB, dMMR, MSI, and PD-L1 AMP are different genetic alterations that occur in many cancers, they may be inherently related. In an analysis of 11,348 cancer patients,
27% of patients with TMB-H exhibited MSI-H, and 70% of MSI-H cases had high
TMB. 46 An analysis of 100,000 cancer genomes from TCGA, found that the 83% of MSI-H samples had high TMB. 21 By contrast, in this study, we found that Chinese cancer patients showing TMB-H exhibited relatively low rates of MSI-H and dMMR.
On the other hand, about the 89% of Chinese cancer patients with an MSI-H status belonged to the TMB-H group. These results indicate that MSI-H can cause TMB-H, but TMB-H is not primarily caused by MSI-H.
We found that 32.14% of Chinese patients with cancer showing MSI-H exhibited dMMR. This overlap between the MSI-H and dMMR cases is higher than what was previously reported (13.37%). 42 We also found that, on average, dMMR CRC carried 15 folds more NSM (1567 vs. 106 NSM) than MMR-proficient CRC, in accordance with a previous report (1782 vs. 73 NSM, respectively). 11 These findings can be interpreted based on data from a previous study regarding the hypermutation of human cancers. This study found that TMB of >100 Mut/Mb may be classified as MSS but contain MMR and replicative polymerase mutations resulting in replication repair deficiency. 47 Moreover, TMB values of 10-100 Mut/Mb were mostly associated with MSI-H and also had high levels of dMMR. This study, therefore, explains to a certain extent why TMB-H, MSI-H, and dMMR do not completely overlap and indicates that there may be several additional underlying causes of TMB-H, for example, replicative polymerase mutations.
Moreover, a recent study has suggested that the underlying causes of these four biomarkers may differ. High TMB and MSI are caused by defects in the DNA damage repair system, 48 which is composed of many proteins in addition to MMR components, including homologous recombination repair element RecA/Rad51 49 and nonhomologous end joining repair element Ku70/Ku80. 50 Research has shown that in the absence of MSI, mutations in DNA polymerase (POLE) can lead to TMB-H. 51 This study has several limitations. First, we only collected information on cancer type, while demographic and clinical characteristics such as age, gender, and tumor stage were not recorded. Therefore, we cannot conduct more detailed subgroup or stratification analyses to obtain more clinical information, for example, investigating whether TMB is related to age and treatment type. Second, the cut-off values for classification into the MSI-H and TMB-H categories were relative and were not based on the results of clinical trials. The assessment cancer-specific thresholds of these biomarkers by comprehensive analysis of clinical outcomes and patient characteristics would be more valuable for clinical application.
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In conclusion, our study characterized the distributions of TMB, MSI, dMMR, and PD-L1 AMP in Chinese patients with cancer and investigated the relevance of these biomarkers. Although these biomarkers could be used to identify cancer patients who may respond to immunotherapy, they cannot perfectly predict the efficacy of immunotherapy. More extensive studies investigating new biomarkers or a combination of biomarkers are therefore needed. 
